Skip to content
10-Q

Quarterly Report

LEXICON PHARMACEUTICALS, INC. LXRX

0001062822-26-000101

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 444.2M sh
Shares Diluted Q1 2026 · Mar 31, 2026 400.24M sh
Shares Diluted Q1 2026 · Mar 31, 2025 362.07M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$14.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$43.78M
Long Term Debt Q1 2026 · Mar 31, 2026 $49.68M
Long Term Debt Q1 2026 · Dec 31, 2025 $49.41M
Short Term Debt Q1 2026 · Mar 31, 2026 $0
Short Term Debt Q1 2026 · Dec 31, 2025 $4.6M
Short Term Investments Q1 2026 · Mar 31, 2026 $132.57M
Short Term Investments Q1 2026 · Dec 31, 2025 $61.9M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $38.09M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $34.33M
Stockholders Equity Q1 2026 · Mar 31, 2026 $202.86M
Stockholders Equity Q1 2026 · Dec 31, 2025 $107.54M
Current Liabilities Q1 2026 · Mar 31, 2026 $9.9M
Current Liabilities Q1 2026 · Dec 31, 2025 $20.87M
Total Liabilities Q1 2026 · Mar 31, 2026 $65.96M
Total Liabilities Q1 2026 · Dec 31, 2025 $77.45M
Current Assets Q1 2026 · Mar 31, 2026 $186.03M
Current Assets Q1 2026 · Dec 31, 2025 $101.9M
Total Assets Q1 2026 · Mar 31, 2026 $268.82M
Total Assets Q1 2026 · Dec 31, 2025 $184.99M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.07
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 −$0.07
Sga Expense Q1 2026 · Mar 31, 2026 $9.23M
Sga Expense Q1 2026 · Mar 31, 2025 $11.61M
Rd Expense Q1 2026 · Mar 31, 2026 $12.76M
Rd Expense Q1 2026 · Mar 31, 2025 $15.3M
Net Income Q1 2026 · Mar 31, 2026 −$1.04M
Net Income Q1 2026 · Mar 31, 2025 −$25.3M
Operating Income Q1 2026 · Mar 31, 2026 −$996K
Operating Income Q1 2026 · Mar 31, 2025 −$25.68M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $108K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $30K